市场调查报告书
商品编码
1355818
双歧桿菌市场规模 - 按产品类型(长双歧桿菌、短双歧桿菌、婴儿双歧桿菌、动物双歧桿菌、乳双歧桿菌)、应用、最终用途、配销通路和全球预测,2023 - 2032Bifidobacterium Market Size - By Product Type (Bifidobacterium Longum, Bifidobacterium Breve, Bifidobacterium Infantis, Bifidobacterium Animalis, Bifidobacterium Lactis), Application, End Use, Distribution Channel & Global Forecast, 2023 - 2032 |
在对众多健康益处的持续研究的推动下,双歧桿菌市场规模从 2023 年到 2032 年的复合年增长率预计将达到 8%。
多项科学研究揭示了双歧桿菌对肠道健康、免疫功能和整体健康的正面影响。因此,消费者越来越多地寻求含有双歧桿菌的产品来解决消化问题、增强免疫力并主动支持健康。越来越多的研究不仅增强了消费者的信心,还鼓励创新和新配方的开发,以扩大基于双歧桿菌的产品的可用性和应用。
双歧桿菌市场根据产品类型、应用、最终用途、配销通路和地区进行分类。
就产品类型而言,预计到2032 年,动物双歧桿菌细分市场的市场规模将获得显着增长。这种增长可归因于动物双歧桿菌作为益生菌菌株的重要性日益增加,因为它们具有潜在的健康益处,特别是在支持消化健康和免疫。 2022 年 6 月发表的一项研究发现,补充动物双歧桿菌亚种。乳酸(Bifal)和精胺酸(Arg)可以显着提高人类认知能力,尤其是老年人。为此,消费者越来越多地寻求含有动物双歧桿菌的产品,以改善肠道微生物群和整体健康。
根据应用情况,製药领域的双歧桿菌产业将在 2023 年至 2032 年实现强劲成长。双歧桿菌菌株越来越多地用于医药产品,特别是益生菌补充剂和用于解决各种健康状况的药物。最近,製药公司正在将有益的益生菌纳入配方中,因为它们具有增强整体健康和福祉的潜力。製药业益生菌研发投资的激增以及对基于益生菌的製药解决方案的需求不断增长将促进该领域的成长。
从区域来看,由于人们对健康和保健的高度重视,以及人们对肠道健康重要性和益生菌作用的认识不断增强,到 2032 年,欧洲双歧桿菌市场将大幅成长。该地区消费者对益生菌产品的需求较高,包括乳製品、补充剂和含有双歧桿菌菌株的功能性食品。此外,有利的监管框架和指导方针将支持市场成长。
Bifidobacterium Market size is poised to 8% CAGR from 2023 to 2032, propelled by continuous research for numerous health benefits.
Several scientific studies have revealed the positive impacts of bifidobacterium on gut health, immune function, and overall well-being. As a result, consumers are increasingly seeking products containing bifidobacterium to address digestive issues, boost immunity, and support health proactively. The growing body of research is not only fostering consumer confidence but also encouraging innovations and the development of new formulations for expanding the availability and application of bifidobacterium-based products.
The bifidobacterium market is categorized based on product type, application, end use, distribution channel, and region.
With respect to product type, the market size from the bifidobacterium animalis segment is projected to gain significant traction through 2032. The growth can be attributed to the rising importance of bifidobacterium animalis as probiotic strains for their potential health benefits, particularly in supporting digestive health and immunity. A study published in June 2022 found that supplementing with Bifidobacterium animalis subsp. lactis (Bifal) and arginine (Arg) could significantly boost human cognition, particularly in older adults. To that end, consumers are increasingly seeking products containing bifidobacterium animalis to improve gut microbiome and overall well-being.
Based on application, the bifidobacterium industry from the pharmaceutical segment will record robust growth from 2023-2032. Bifidobacterium strains are increasingly utilized in pharmaceutical products, particularly in probiotic supplements and medications for addressing various health conditions. Lately, pharmaceutical companies are incorporating beneficial probiotics into formulations due to their potential to enhance overall health and well-being. The surging number of probiotic R&D investments in the pharmaceutical industry along with the growing demand for probiotic-based pharmaceutical solutions will add to the segment growth.
Regional, the bifidobacterium market in Europe will witness considerable growth up to 2032 due to the strong emphasis on health and wellness along with the growing awareness of the importance of gut health and the role of probiotics. There has been higher consumer demand for probiotic products, including dairy, supplements, and functional foods containing Bifidobacterium strains in the region. Additionally, favorable regulatory frameworks and guidelines will support the market growth.